 in this presentation, we are going to focus on what we are doing in terms of shareholder value creation and how we can continue to build resiliency in terms of our revenue profile.  so first of all, we are a diversified and resilient business with multiple growth drivers in fast-growing end markets like biopharma, clinical diagnostics and life sciences research.  secondly, we are a leader in biopharma services for therapy selection.  thirdly, we are a leader in companion diagnostics.  finally, we are the market leader in therapeutic oligonucleotide therapeutics.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 _ =    # 2    # 3    # 4    # 5    # 6    # 7    # 8    # 9    # 10    # 11    # 12    # 13    # 14    # 15    # 16    # 17    # 18 